Trial Profile
A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ILLUMINATE
- 15 Sep 2011 Results reported in a Vertex Pharmaceuticals media release and published in the New England Journal of Medicine.
- 20 Jul 2011 Actual initiation date is Oct 2008 added as reported by ClinicalTrials.gov.
- 25 May 2011 Work productivity results presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.